UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended October 31, 2000
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Commission file number 1-8696
COMPETITIVE TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Delaware 36-2664428
(State or other jurisdiction of (I.R.S. Employer
Identification No.)
incorporation or organization)
1960 Bronson Road
Fairfield, Connecticut 06430
(Address of principal executive (Zip Code)
offices)
Registrant's telephone number, including area code: (203) 255-6044
N/A
Former name, former address and former fiscal year, if
changed since last report
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15 (d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90
days. Yes X . No .
Common Stock outstanding as of December 1, 2000 - 6,112,285 shares
Exhibit Index on sequentially numbered page 16 of 18.
Page 1 of 18 sequentially numbered pages
COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES
INDEX
PART I. FINANCIAL INFORMATION Page No.
Item 1. Condensed Financial Statements
A. Financial Statements (Unaudited)
Consolidated Balance Sheets at
October 31, 2000 and July 31, 2000 3
Consolidated Statements of Operations for the
three months ended October 31, 2000 and 1999 4
Consolidated Statement of Changes in
Shareholders' Interest for the three
months ended October 31, 2000 5
Consolidated Statements of Cash Flows for the
three months ended October 31, 2000 and 1999 6
Notes to Consolidated Financial Statements 7-10
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of
Operations 11-15
Item 3. Quantitative and Qualitative Disclosures
About Market Risk 15
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K 16
Signatures 17
PART I. FINANCIAL INFORMATION
COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES
Consolidated Balance Sheets
October 31, 2000 and July 31, 2000
(Unaudited)
October 31, July 31,
2000 2000
ASSETS
Current assets:
Cash and cash equivalents $ 1,235,485 $ 1,716,375
Short-term investments, at market 6,329,373 5,000,054
Receivables, including $9,925 receivable
from related parties in October and July 409,470 2,420,180
Prepaid expenses and other current assets 121,864 149,483
Total current assets 8,096,192 9,286,092
Property and equipment, at cost, net 115,357 115,518
Investments 1,525,685 1,525,685
Intangible assets acquired, principally
licenses and patented technologies, net 1,132,002 1,166,670
TOTAL ASSETS $ 10,869,236 $ 12,093,965
LIABILITIES AND SHAREHOLDERS' INTEREST
Current liabilities:
Accounts payable $ 100,361 $ 65,443
Accrued liabilities 1,392,854 2,100,410
Total current liabilities 1,493,215 2,165,853
Commitments and contingencies -- --
Shareholders' interest:
5% preferred stock, $25 par value 60,675 60,675
Common stock, $.01 par value 61,907 61,907
Capital in excess of par value 27,053,542 27,053,542
Treasury stock (common), at cost;
43,300 shares in October (366,951) --
Accumulated deficit (17,433,152) (17,248,012)
Total shareholders' interest 9,376,021 9,928,112
TOTAL LIABILITIES AND SHAREHOLDERS'
INTEREST $ 10,869,236 $ 12,093,965
See accompanying notes
PART I. FINANCIAL INFORMATION (Continued)
COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
for the three months ended October 31, 2000 and 1999
(Unaudited)
2000 1999
Revenues:
Retained royalties $ 462,669 $ 444,730
Revenues under service contracts 909 126,097
463,578 570,827
Costs of technology management
services 392,479 564,084
General and administration expenses,
of which $41,947 and $27,557 were
paid to related parties in 2000
and 1999, respectively 375,944 228,663
768,423 792,747
Operating loss (304,845) (221,920)
Interest income 123,904 81,123
Other income (expense), net (4,199) (269)
Net loss (185,140) (141,066)
Other comprehensive income:
Net unrealized holding gains
on available-for-sale securities -- 10,417
Comprehensive loss $ (185,140) $ (130,649)
Net loss per share:
Basic and diluted $ (0.03) $ (0.02)
Weighted average number of common
shares outstanding:
Basic and diluted 6,179,313 6,002,640
See accompanying notes
PART I. FINANCIAL INFORMATION (Continued)
COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES
Consolidated Statement of Changes in Shareholders' Interest
For the three months ended October 31, 2000
(Unaudited)
<TABLE>
<CAPTION>
Preferred Stock
Shares Common Stock Capital in
issued and Shares excess of Treasury Stock Accumulated
outstanding Amount issued Amount par value Shares held Amount Deficit
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Balance - July 31, 2000 2,427 $60,675 6,190,785 $61,907 $27,053,542 -- $ -- $(17,248,012)
Purchase of
treasury stock. . . . . (43,300) (366,951)
Net loss. . . . . . . . . (185,140)
Balance - October 31, 2000 2,427 $60,675 6,190,785 $61,907 $27,053,542 (43,300) $(366,951) $(17,433,152)
</TABLE>
See accompanying notes
PART I. FINANCIAL INFORMATION (Continued)
COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
for the three months ended October 31, 2000 and 1999
(Unaudited)
2000 1999
Cash flow from operating activities:
Loss from operations $ (185,140) $ (141,066)
Noncash items included in
loss from operations:
Depreciation and amortization 53,591 51,549
Directors' stock and stock retirement
plan accruals 34,013 35,564
Other noncash items -- 3
Net changes in various operating
accounts:
Receivables 2,010,710 1,170,865
Prepaid expenses and other current
assets 27,619 33,218
Accounts payable and accrued
liabilities (706,651) (415,469)
Net cash flow from operating activities 1,234,142 734,664
Cash flow from investing activities:
Disposals (purchases) of property and
equipment, net (18,762) (15,220)
Purchases of other short-term investments (1,329,319) (57,439)
Net cash flow from investing activities (1,348,081) (72,659)
Cash flow from financing activities:
Proceeds from issuance of common stock, net -- 105,500
Purchases of treasury stock (366,951) (117,872)
Net cash flow from financing activities (366,951) (12,372)
Net (decrease) increase in cash and cash
equivalents (480,890) 649,633
Cash and cash equivalents, beginning
of period 1,716,375 908,514
Cash and cash equivalents, end of period $ 1,235,485 $ 1,558,147
See accompanying notes
PART I. FINANCIAL INFORMATION (Continued)
COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Unaudited)
1. Interim Financial Statements
Interim financial information presented in the accompanying
financial statements and notes hereto is unaudited.
The year-end balance sheet data was derived from audited
financial statements but does not include all disclosures
required by generally accepted accounting principles. Certain
amounts have been reclassified to conform with the presentation
in financial statements for fiscal 2001.
In the opinion of management, all adjustments which are
necessary to present the financial statements fairly in
conformity with generally accepted accounting principles,
consisting only of normal recurring adjustments, have been made.
The interim financial statements and notes thereto as well
as the accompanying Management's Discussion and Analysis of
Financial Condition and Results of Operations should be read in
conjunction with the Company's Annual Report on Form 10-K for the
year ended July 31, 2000.
2. Net Loss Per Share
The following table sets forth the computations of basic and
diluted net loss per share.
Quarter
ended October 31,
2000 1999
Net loss applicable to common stock:
Basic and diluted $ (185,140) $ (141,066)
Weighted average number of common
shares outstanding 6,179,313 6,002,640
Effect of dilutive securities:
Stock options -- --
Stock warrants -- --
Weighted average number of common
shares outstanding and dilutive
securities 6,179,313 6,002,640
Net loss per share of
common stock:
Basic and diluted $ (0.03) $ (0.02)
At October 31, 2000 and 1999, respectively, options and
warrants to purchase 474,517 and 647,042 shares of common stock
were outstanding but were not included in the computation of
earnings per share because they were anti-dilutive.
3. Short-term Investments
The Company had no available-for-sale securities at October
31, 2000. For the quarters ended October 31, 2000 and October
31, 1999, there were no sales of available-for-sale securities.
Cost is based on specific identification in computing realized
gains.
A reconciliation detailing amounts reported in net income and
other comprehensive income for the quarter ended October 31, 1999
follows:
Quarter ended
October 31, 1999
Accumulated other comprehensive loss:
Accumulated net unrealized holding losses
on available-for-sale securities,
beginning of period $(15,625)
Other comprehensive income:
Holding gains arising during the period 10,417
Accumulated other comprehensive loss $ (5,208)
No tax effect is reported on the Company's unrealized gains
on securities because the Company has capital loss carryforwards.
4. Receivables
Receivables were:
October 31, July 31,
2000 2000
Royalties $ 367,466 $2,347,176
Other 42,004 73,004
$ 409,470 $2,420,180
5. Accrued Liabilities
Accrued liabilities were:
October 31, July 31,
2000 2000
Royalties payable $1,004,198 $1,780,988
Accrued compensation 208,727 147,766
Deferred revenues 9,610 10,521
Other 170,319 161,135
$1,392,854 $2,100,410
6. Contingencies
Litigation
On May 4, 1999, Metabolite Laboratories, Inc. (MLI) and
Competitive Technologies, Inc. (CTT or the Company) (collectively
plaintiffs) filed a complaint and jury demand against Laboratory
Corporation of America Holdings d/b/a LabCorp (LabCorp) in the
United States District Court for the District of Colorado. The
complaint alleges, among other things, that LabCorp owes
plaintiffs royalties for homocysteine assays performed during and
since the summer of 1998 using methods and materials falling
within the claims of a patent owned by CTT. CTT licensed the
patent non-exclusively to MLI and MLI sublicensed it to LabCorp.
Plaintiffs claim LabCorp's actions constitute breach of contract
and patent infringement. Their claim seeks an injunction
ordering LabCorp to perform all its obligations under its
agreement, to cure past breaches, to provide an accounting of
wrongfully withheld royalties and to refrain from infringing the
patent. Plaintiffs also seek unspecified money and exemplary
damages and attorneys' fees, among other things. LabCorp has
filed an answer and counterclaims alleging noninfringement,
patent invalidity and patent misuse. Discovery has been
completed. Trial is scheduled to begin in April 2001. Through
October 31, 2000, CTT had incurred approximately $88,000 in
unreimbursed litigation expenses related to this case. CTT is
unable to estimate the related legal expenses it may incur in
this suit and has recorded no revenue for these withheld
royalties.
The University of Colorado Foundation, Inc., the University
of Colorado, the Board of Regents of the University of Colorado,
Robert H. Allen and Paul A. Seligman, plaintiffs, previously
filed a lawsuit against American Cyanamid Company, defendant, in
the United States District Court for the District of Colorado.
This case involved a patent for an improved formulation of
Materna(TM), a prenatal vitamin compound sold by defendant. While
the Company was not and is not a party to this case, the Company
had a contract with the University of Colorado to license
University of Colorado inventions to third parties. As a result
of this contract, the Company is entitled to share approximately
18% of damages awarded to the University of Colorado, if any,
after deducting the expenses of this suit. On November 19, 1999,
the United States Court of Appeals for the Federal Circuit
vacated a July 7, 1997 judgment by the District Court in favor of
plaintiffs for approximately $44 million and remanded the case to
the District Court for further proceedings. On July 7, 2000, the
District Court concluded that Robert H. Allen and Paul A.
Seligman were the sole inventors of the reformulation of Materna(TM)
that was the subject of the patent and that defendant is liable
to them and the other plaintiffs on their claims for fraud and
unjust enrichment. The District Court also reopened all issues
of damages and ordered a retrial to determine the nature and
amount of damages to be paid by defendant. The damages retrial
is scheduled to begin in March 2001. The Company cannot predict
the amount of its share of the judgment, if any, which may
ultimately be awarded. The Company has recorded no potential
judgment proceeds in its financial statements to date. The
Company has agreed to pay its proportionate share of out-of-
pocket costs and expenses (excluding attorneys' fees) incurred
since August 1, 2000 through the conclusion of this suit. This
agreement provides for the Company's reimbursement from potential
judgment proceeds, if any, for costs and expenses it may pay.
The Company recorded patent litigation expenses of approximately
$21,000 as costs of technology management services in the first
quarter of fiscal 2001 and to date. The Company is unable to
estimate the costs and expenses it may incur in the future,
principally relating to expert witnesses in the damages case. The
Company records these expenses as they are incurred and will
record their reimbursement, if any, when the judgment is finally
determined.
In 1989 University Optical Products Co. (UOP), a majority-
owned subsidiary of CTT that had developed a computer-based
system to manufacture specialty contact lenses, intraocular
lenses and other precision optical products, sold substantially
all its assets to Unilens Corp. USA (Unilens). The proceeds of
the sale included an installment obligation for $5,500,000
payable at a minimum of $250,000 per year beginning in January
1992. Due to the uncertainty of the timing and amount of future
cash flows, income on the installment obligation is recorded net
of related expenses as the payments are received. Cash received
in excess of the fair value assigned to the original obligation
is recorded as other income from continuing operations. As cash
proceeds are received, CTT records a 4% commission expense
payable to its joint venture partner, Optical Associates, Limited
Partnership (OALP). Unilens made no payments in fiscal 2001 or
2000. Through October 31, 2000, the Company had received
aggregate cash proceeds of approximately $1,011,000 from the
January 1989 sale of UOP's assets to Unilens.
In November 1991, a lawsuit was filed in Connecticut against
CTT, its wholly owned subsidiary, Genetic Technology Management,
Inc. (GTM), its majority-owned subsidiary, UOP, and one current
and several former directors on behalf of the 59 limited partners
of OALP. The complaint alleges, among other things, that the
January 1989 sale of UOP's assets to Unilens violated the
partnership agreement and that OALP is entitled to the full
proceeds of the sale to Unilens. The complaint claims, among
other things, money damages and treble and punitive damages in an
unspecified amount and attorneys' fees. The Company believes
that the asserted claims are without merit and intends to
continue to defend vigorously the action instituted by
plaintiffs. An attorney referee has heard the case. In November
2000, the Company made a motion to dismiss the case and the
attorney referee instructed both parties to prepare their final
briefs. The Company anticipates the attorney referee's decision
by July 31, 2001. CTT recognized other expenses of $4,199 and
$269 in the first quarter of fiscal 2001 and 2000, respectively,
for legal expenses related to this suit.
PART I. FINANCIAL INFORMATION (Continued)
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
Financial Condition and Liquidity
At October 31, 2000, cash and cash equivalents of $1,235,485
were $480,890 lower than cash and cash equivalents of $1,716,375
at July 31, 2000. Operating activities provided $1,234,142,
investing activities used $1,348,081 and financing activities
used $366,951.
In addition, Competitive Technologies, Inc. (CTT) and its
majority-owned subsidiaries (the Company) held $6,329,373 in
short-term investments at October 31, 2000. These investments
are available for the Company's future operating, investing and
financing activities.
The Company's net loss for the quarter ended October 31,
2000, included non-cash charges of approximately $54,000 for
depreciation and amortization and approximately $34,000 for
directors' stock and stock retirement plan accruals.
In general, changes in various operating accounts result
from changes in the timing and amounts of cash flows before and
after the end of the period. The most substantial changes in
operating accounts were the $1,979,710 decrease in royalties
receivable and the $776,790 decrease in royalties payable. These
changes in royalties receivable and payable reflect the Company's
normal cycle of royalty collections and payments.
During the three months ended October 31, 2000, the Company
purchased $1,329,319 of short-term investments.
In October 1998, the Board of Directors authorized CTT to
repurchase up to 250,000 shares of its common stock. CTT may
repurchase shares on the open market or in privately negotiated
transactions at times and in amounts determined by management
based on its evaluation of market and economic conditions. CTT
repurchased 43,300 shares of its common stock for $366,951 in
cash in the quarter ended October 31, 2000. In addition, CTT
repurchased another 34,500 shares for $252,039 in cash during
November 2000. From October 1998 through November 30, 2000, CTT
has repurchased 152,600 shares of its common stock for a total of
$1,004,915. Through November 30, 2000, CTT had reissued 74,800
of those repurchased shares rather than issue new shares to
satisfy employees' exercises of stock options and contribution
requirements under other employee and director plans payable in
shares of CTT's common stock.
At October 31, 2000, the Company had no outstanding
commitments for capital expenditures.
The Company carries liability insurance, directors' and
officers' liability insurance and casualty insurance for owned or
leased tangible assets. It does not carry key person life
insurance. There are no legal restrictions on payments of
dividends by CTT.
The Company continues to pursue additional technology
commercialization opportunities. If and when such opportunities
are consummated, the Company may commit capital resources to
them.
The Company does not believe inflation had a significant
impact on its operations during fiscal 2001 or 2000 or that it
will have a significant impact on operations during the next
twelve-month operating period.
Currently Vector Vision, Inc. (VVI), CTT's 51.6% owned
subsidiary, is operationally inactive. The Company, the inventor
and others supported VVI's video compression software development
activities in the past. Certain of VVI's proprietary technology
has been accepted in a portion of the MPEG-4 standard, an
international standard for low bandwidth applications such as
video teleconferencing, video databases and wireless video
access.
The Company is involved in three pending litigation matters.
Full descriptions of them are reported in Note 6 to the
accompanying Consolidated Financial Statements.
At October 31, 2000, the Company had cash and cash
equivalents of $1,235,485, short-term investments of $6,329,373,
royalties receivable of $367,466 and royalties payable of
$1,004,198. Total assets were $10,869,236, total liabilities
were $1,493,215 and total shareholders' interest was $9,376,021.
Based on the Company's current expectations, it anticipates
that currently available funds will be sufficient to finance cash
needs for the foreseeable future for its current operating
activities. However, expansion of the Company's business is
subject to many factors outside the Company's control or that it
cannot currently anticipate, including without limitation
business opportunities that may arise in the future.
Accordingly, there can be no assurance that the Company's current
expectations regarding the sufficiency of currently available
funds will prove to be accurate.
Results of Operations - Three Months Ended October 31, 2000
(First Quarter of Fiscal 2001) vs. Three Months Ended October 31,
1999 (First Quarter of Fiscal 2000)
Total revenues for the first quarter of fiscal 2001 were
$463,578, $107,249 (19%) lower than for the first quarter of
fiscal 2000.
For the first quarter of fiscal 2001, retained royalties
were $462,669, $17,939 (4%) higher than for the first quarter of
fiscal 2000.
In the first quarter of fiscal 2001, retained royalty
revenues on our endoscopic ligator were less than $500 and
approximately $78,000 lower than in the first quarter of fiscal
2000. An arbitrator ruled that claims in our current patent were
invalid. We have amended our claims and filed for a
reexamination of our patent. Since the arbitrator's ruling,
licensees of this technology have withheld royalties. Our
retained royalties from the endoscopic ligator were approximately
$138,000 and $247,000 for the fiscal years ended July 31, 2000
and 1999, respectively. Although we expect our patent to reissue
during fiscal 2001 and we believe we will then be entitled to all
withheld and future royalties, we cannot predict when, if ever,
licensees will resume remitting royalties for this technology.
Other changes in retained royalty revenues reflect new
option and license issue fees and changes in the timing of
royalties reported by licensees and in licensees' sales of
licensed products. Historically, the Company's royalty revenues
in its first and third fiscal quarters have been lower than in
its second and fourth fiscal quarters.
Revenues under service contracts for the first quarter of
fiscal 2001 were $125,188 lower than for the first quarter of
fiscal 2000. The Company is not actively seeking additional fee-
for-service contracts, although it may agree to them in the
future in certain circumstances. In the first quarter of fiscal
2000, the Company earned revenues from two non-recurring service
contracts, one for a government agency and one for a domestic
start-up corporation. Many of the Company's service contracts
are one-time arrangements unique to a particular client at a
particular time.
Total operating expenses for the first quarter of fiscal
2001 were $768,423. This was $24,324 (3%) lower than for the
quarter ended October 31, 1999. Reductions in direct costs
related to service contracts and in personnel and related
expenses were partially offset by increases in patent litigation
expenses and consultants' fees and expenses. The Company
employed approximately 10 people full-time in the first quarter
of fiscal 2001 compared with 14 in the first quarter of fiscal
2000. The Company is currently seeking to add technology
commercialization professionals to its staff in the near term.
Until we can identify and hire additional staff, we are using
consultants for certain services.
Costs of technology management services for the first
quarter of fiscal 2001 were $392,479, $171,605 (30%) lower than
for the first quarter of fiscal 2000, as more fully discussed
below.
Costs related to licensing and retained royalties were
approximately $27,000 higher in the first quarter of fiscal 2001
than in the first quarter of fiscal 2000. Approximately $21,000
of this increase resulted from the Company's agreement to pay its
proportionate share of out-of-pocket expenses (excluding
attorneys' fees) from August 1, 2000 in the Materna(TM) prenatal
vitamin litigation (See Note 6 to the accompanying Consolidated
Financial Statements). Costs related to licensing and retained
royalties include personnel costs (including benefits and
overheads) associated with patenting and licensing, patent
litigation and enforcement expenses (net of reimbursements)
related to several matters, and domestic and foreign patent
prosecution and maintenance expenses.
Costs related to service contracts were approximately
$75,000 lower for the first quarter of fiscal 2001 than for the
first quarter of fiscal 2000. This decrease results from the
Company's move away from fee-for-service contracts to a focus on
licensing and enforcing intellectual property rights and
investing in ventures where, in addition to making cash
investments, we can provide intellectual property and technology
commercialization expertise.
Costs associated with new client development for the first
quarter of fiscal 2001 (principally personnel costs, including
benefits and overheads) were approximately $124,000 lower than
for the first quarter of fiscal 2000. We are seeking to hire
technology commercialization professionals in this function.
General and administration expenses in the first quarter of
fiscal 2001 were $147,281 (64%) higher than in the first quarter
of fiscal 2000. In addition to higher consultants' fees and
expenses, the Company's expenses increased in the areas of
general and administrative functions. The increase in expenses
was partially offset by the loss of four technology
commercialization professionals.
The net effect of the $107,249 decrease in operating
revenues and the $24,324 decrease in operating expenses was to
increase the Company's operating loss by $82,925 (37%) compared
with the first quarter of fiscal 2000.
Interest income of $123,904 in the first quarter of fiscal
2001 was $42,781 (53%) higher than in the first quarter of fiscal
2000. The Company's average invested balance was approximately
18% higher and its weighted average interest rate was
approximately 1.5% per annum higher than for the first quarter of
fiscal 2000.
The Company has approximately $13,185,000 of Federal net
operating loss carryforwards of which approximately $4,343,000
and $4,371,000 expire in fiscal 2001 and 2002, respectively. The
Company's ability to derive future tax benefits from its net
deferred tax assets is uncertain and therefore the valuation
allowance completely offsets them.
In December 1999, the staff of the Securities and Exchange
Commission issued Staff Accounting Bulletin No. 101, "Revenue
Recognition in Financial Statements" (SAB 101). SAB 101 as
amended to date (a) summarizes certain of the staff's views in
applying generally accepted accounting principles to revenue
recognition in financial statements and (b) requires companies to
analyze their revenue recognition policies for compliance with
generally accepted accounting principles summarized in SAB 101 no
later than the fourth quarter of fiscal years beginning after
December 15, 1999. The Company is currently assessing the impact
of SAB 101 on its financial statements.
Forward-Looking Statements
Statements about the Company's future expectations,
including development and regulatory plans, and all other
statements in this Quarterly Report on Form 10-Q other than
historical facts, are "forward-looking statements" within the
meaning of applicable Federal Securities Laws and are not
guarantees of future performance. These statements involve risks
and uncertainties related to market acceptance of and competition
for the Company's licensed technologies and other risks and
uncertainties inherent in the Company's business, including those
set forth in Item 1 of the Company's Annual Report on Form 10-K
for the year ended July 31, 2000, and other factors that may be
described in the Company's filings with the Securities and
Exchange Commission, and are subject to change at any time. The
Company's actual results could differ materially from these
forward-looking statements. The Company undertakes no obligation
to update publicly any forward-looking statement.
Item 3. Quantitative and Qualitative Disclosures About Market
Risk
Not applicable.
PART II - OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K Page
A) Exhibits
11.1 Schedule of computation of earnings per
share for the three months ended
October 31, 2000 and 1999. 18
27.1 Financial Data Schedule (EDGAR only).
B) Reports on Form 8-K
No reports on Form 8-K were filed during the quarter for
which this report is filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
COMPETITIVE TECHNOLOGIES, INC.
(Registrant)
Date: December 15, 2000 By: s/ Frank R. McPike, Jr.
Frank R. McPike, Jr.
President,
Chief Executive Officer,
Chief Financial Officer
and Authorized Signer
